Cyclana Bio's ambitious clinical observational study, PEMP, has received Health Research Authority (HRA) and Research Ethics Committee (REC) approval, marking a significant milestone in the company's mission to revolutionize women's health research. With the recruitment of the first patients at Peterborough City Hospital and the Rosie Hospital, Cambridge, the study is set to delve into the complex world of endometriosis, a condition affecting 1 in 10 women worldwide.
Unlocking the Mysteries of Endometriosis
Endometriosis, a debilitating condition with limited treatment options, has long been a challenge for medical science. Cyclana Bio's innovative approach involves using human data and cells from menstrual fluid and biopsies to create 3D in vitro models of the disease. These models will provide valuable insights into the basic biology of endometriosis, potentially leading to the identification of novel druggable targets for therapeutic development.
The study's primary objective is to compare tissue-level dynamics in healthy women to those with endometriosis, aiming to uncover common underlying causal mechanisms. By doing so, Cyclana Bio hopes to determine whether a universal treatment can be developed or if personalized medicine is necessary. This approach challenges the traditional focus on intracellular mechanisms, which have historically failed to yield optimal treatments.
A Personalized Medicine Perspective
Dr. Léa Wenger, CEO and Co-Founder of Cyclana Bio, emphasizes the potential of their tissue-first methodology. She believes it can bridge the gap in drug discovery by revealing shared underlying mechanisms between patients. This perspective is particularly intriguing, as it suggests that endometriosis may have a more uniform cause than previously thought, which could lead to more effective and generalized treatments.
Addressing the Need for Better Treatments
The impact of endometriosis on women's lives cannot be overstated. With limited treatment options, women suffering from this condition often face prolonged suffering. Cyclana Bio's study, funded by a £5 million pre-seed funding round, aims to address this critical need. By understanding the disease's mechanisms and identifying druggable targets, the company hopes to develop life-changing therapies that can significantly improve the lives of millions of women.
A Collaborative Effort
The study is a collaborative effort between Cambridge University Hospitals NHS Foundation Trust and the North West Anglia NHS Foundation Trust. Led by Chief Investigator M. Saikat Banerjee at the Rosie Hospital and Principal Investigator M. Lukasz Polanski at Peterborough City Hospital, the research team is dedicated to uncovering the causal mechanisms of endometriosis. Their work highlights the importance of interdisciplinary collaboration in advancing medical research.
Looking Ahead
As the study progresses, Cyclana Bio aims to expand its whole tissue-based methodology to other underserved chronic inflammatory indications with similar tissue-level mechanisms. This expansion could revolutionize the approach to treating various inflammatory conditions, not just endometriosis. The company's commitment to innovation and collaboration positions it as a leader in the field of women's health research, offering hope for improved treatments and a better quality of life for countless women.
